Search | Clinical Trials Finder

Conditions: Corneal Epithelial Wound Healing
Interventions: 0.00025% Lacripep ophthalmic solution and Placebo; Drug
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 21 Years to 55 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Fort Belvoir, Virginia

Conditions: Anesthesia, Local
Interventions: AG-920, Placebo; Drug
Lead sponsor: American Genomics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Dry Eye Disease
Interventions: iNexin™ (0.08% aCT1), iNexin™ (0.4% aCT1), iNexin™ (2.0% aCT1), Vehicle (eye drop formulation without aCT1); Drug
Lead sponsor: Xequel Bio, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Non-Infectious Anterior Uveitis
Interventions: 8% Dexamethasone Sodium Phosphate - Visulex, 15% Dexamethasone Sodium Phosphate - Visulex, Prednisolone Acetate (1%) Eye Drops; Drug
Lead sponsor: Aciont Inc; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 6
States / cities: Cambridge, Massachusetts • Charlotte, North Carolina • Fargo, North Dakota + 3 more

Conditions: Age-related Wet Macular Degeneration
Interventions: CG-P5 peptide, Placebo, Aflibercept Injection [Eylea]; Drug
Lead sponsor: Caregen Co. Ltd.; Industry
Eligibility: 50 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Manchester, Connecticut • Deerfield Beach, Florida • Augusta, Georgia + 4 more

Conditions: Glaucoma
Interventions: AR-102 0.003% Ophthalmic Solution, AR-102 0.005% Ophthalmic Solution, AR-102 0.01% Ophthalmic Solution, AR-102 0.03% Ophthalmic Solution, AR-102 Vehicle Ophthalmic Solution; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 8
States / cities: Pasadena, California • Petaluma, California • Brooksville, Florida + 5 more

Conditions: Dry Eye Syndrome
Interventions: Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.1%), Vehicle Ophthalmic Solution; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 6
States / cities: Waterbury, Connecticut • Indianapolis, Indiana • Lewiston, Maine + 3 more

Conditions: Cataract, Glaucoma, Ocular Hypertension
Interventions: Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%, Commercial IOL; Drug · Device
Lead sponsor: SpyGlass Pharma, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Dry Eye, Dry Eye, Evaporative, Dry Eye Disease, Evaporative Dry Eye, Evaporative Dry Eye Disease, Kerato Conjunctivitis Sicca
Interventions: Miebo; Drug
Lead sponsor: Gordon Schanzlin New Vision; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Diego, California

Conditions: Pterygium
Interventions: CBT-001, Vehicle; Drug
Lead sponsor: Cloudbreak Therapeutics, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 20
States / cities: Dothan, Alabama • Sun City, Arizona • Bakersfield, California + 16 more

Conditions: Hypotrichosis
Interventions: bimatoprost ophthalmic solution 0.03%, bimatoprost vehicle solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Meibomian Gland Dysfunction, Posterior Blepharitis
Interventions: Loteprednol/tobramycin, Loteprednol, B+L Advanced Eye Relief Lubricant Drop; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Asteroid Hyalosis
Interventions: C-KAD Ophthalmic Solution; Drug
Lead sponsor: Chakshu Research, Inc.; Industry
Eligibility: 21 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Mountain View, California

Conditions: Keratoconus, Corneal Ectasia
Interventions: KXL System (15 mW/cm2), KXL System (30 mW/cm2), KXL System (45 mW/cm2), riboflavin ophthalmic solution; Device · Drug
Lead sponsor: American-European Congress of Ophthalmic Surgery; Network
Eligibility: 12 Years and older
Enrollment: 1,721 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 82
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 71 more

Conditions: Dry Eye
Interventions: Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID, Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Thyroid Carcinoma, Radioactive Iodine Level
Interventions: Artificial Tears; Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: bimatoprost 20 µg generation 2, bimatoprost 15 µg generation 2, bimatoprost 10 µg generation 2, bimatoprost 6 µg generation 2, bimatoprost 15 µg generation 1, bimatoprost 10 µg generation 1, bimatoprost 0.03%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 36
States / cities: Artesia, California • La Jolla, California • Los Angeles, California + 31 more

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost 0.03%, travoprost 0.004%, latanoprost 0.005% eye drops; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: San Diego, California

Conditions: Dry Eye Syndrome
Interventions: TheraTears lubricating drops; Other
Lead sponsor: Jenkins Eye Care; Other
Eligibility: 21 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Dry Eye Disease
Interventions: rhNGF 5 μg/mL, rhNGF 10 μg/mL, Vehicle (Placebo solution); Drug
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 10
States / cities: Chandler, Arizona • Torrance, California • Colorado Springs, Colorado + 7 more

Conditions: Erythematous Rosacea
Interventions: 0.18% COL-118 facial gel (1.8 mg brimonidine), 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop), Advanced Eye Relief, COL-118 facial gel vehicle; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Broomall, Pennsylvania

Conditions: Glaucoma, Ocular Surface Disease
Interventions: Xiidra (Lifitegrast ophthalmic solution) 5%; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Fountain Valley, California

Conditions: Healthy
Interventions: Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P); Drug
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Glaucoma, Glaucoma Eye, Glaucoma, Open-Angle
Interventions: Lumega-Z, Dorzolamide Hcl 2% Oph Soln, Placebo; Dietary Supplement · Drug · Other
Lead sponsor: University of the Incarnate Word; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Lacripep for Corneal Wound Healing Study

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease

Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

Ocular Hypotensive Efficacy of AR-102

A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers

A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence

Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis

An Open-Label Study of the Effect of an Ophthalmic Solution on Asteroid Hyalosis

Safety & Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery

A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease

Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System

Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension

Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues

Changes in Tear Osmolarity Over Time With Sustained Use of TheraTears

A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.

Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%

Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

Augmented Macular Pigment-containing Nutraceutical and Central Visual Function